Search results for "opioids."

showing 10 items of 39 documents

Determinants of prescription opioid use: population‐based evidence from Finland

2019

BACKGROUND AND AIMS Previous studies have shown that prescription opioid use is more common in socio-economically disadvantaged communities in the United States. This study examined the area and individual-level determinants of prescription opioid use in Finland during the period 1995-2016. DESIGN Logistic regression analysis using nation-wide data on filled opioid-related prescriptions dispensed at Finnish pharmacies and covered by National Health Insurance. Opioid consumption was linked, using personal identification codes, to population-based data maintained by Statistics Finland, which records individual background and area-level characteristics. SETTING AND PARTICIPANTS Working-age pop…

AdultMaleAdolescent515 Psychologyprescription drugssocio-economic statusprevalencePopulation030508 substance abuseMedicine (miscellaneous)Logistic regressionDrug PrescriptionsYoung Adult03 medical and health sciences0302 clinical medicineOdds RatiomedicineHumans030212 general & internal medicineMedical prescriptioneducationSocioeconomic statusFinlandeducation.field_of_studyopioid useCodeinebusiness.industryCodeine1. No povertyopioidsOdds ratioMiddle Aged3142 Public health care science environmental and occupational healthConfidence intervalpopulation-based3. Good healthAnalgesics OpioidPsychiatry and Mental healthSocioeconomic FactorsOpioid8. Economic growthFemale0305 other medical sciencebusinessmedicine.drugDemographyAddiction
researchProduct

Low morphine doses in opioid-naive cancer patients with pain

2006

Cancer pain can be managed in most patients through the use of the analgesic ladder proposed by the World Health Organization. Recent studies have proposed to skip the second "rung" of the ladder by using a so-called "strong" opioid for moderate pain. However, usual doses of strong opioids commonly prescribed for the third rung of the analgesic ladder may pose several problems in terms of tolerability in opioid-naive patients. The aim of this multicenter study was to evaluate the efficacy and tolerability of very low doses of morphine in advanced cancer patients no longer responsive to nonopioid analgesics. A sample of 110 consecutive opioid-naive patients with moderate-to-severe pain were …

AdultMalePainWHO method cancer pain opioids morphineOpioidDose-Response RelationshipQuality of lifeNeoplasmsWHO methodMedicineHumansCancer painOpioid peptideGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsDose-Response Relationship DrugCancer pain; Morphine; Opioids; WHO method; Adult; Aged; Analgesics Opioid; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Morphine; Neoplasms; Pain; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Morphinebusiness.industryCancerMiddle Agedmedicine.diseaseAnalgesics OpioidClinical trialOpioidsTreatment OutcomeAnesthesiology and Pain MedicineTolerabilityOpioidNeurologyAnesthesiaMorphineFemaleNeurology (clinical)DrugbusinessCancer painmedicine.drug
researchProduct

Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.

2010

Objective: According to experimental findings, oxycodone (OX) could have some advantages over morphine (MO) in clinical models of visceral pain. It was hypothesized that OX could have some advantages over MO in terms of efficacy and dose escalation in pancreatic cancer pain. Methods: Sixty patients with pancreatic cancer with a pain intensity rating of 4/10 who required opioids were included in the study. Patients were randomized to receive 30mg/d of sustained release oral MO or sustained release oral OX (20mg/d). Opioid doses were increased according to the clinical needs. Daily doses of opioids, pain and symptom intensity were recorded at admission (T0) and at weekly intervals for the sub…

AdultMalePancreatic diseaseSettore MED/06 - Oncologia MedicaPopulationPainmorphine; opioids; oxycodone; pancreatic cancer pain; visceral painStatistics Nonparametricpancreatic cancer painPancreatic cancermedicineHumanseducationPain Measurementeducation.field_of_studyMorphinebusiness.industryVisceral painmedicine.diseaseAnalgesics OpioidPancreatic NeoplasmsAnesthesiology and Pain MedicineTreatment OutcomeOpioidAnesthesiaopioidMorphineFemalevisceral painNeurology (clinical)medicine.symptomAnalgesiaCancer painbusinessOxycodoneOxycodonemedicine.drugThe Clinical journal of pain
researchProduct

Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain

2007

The use of supplemental doses of opioids is commonly suggested to manage breakthrough pain. A comparative study of intravenous morphine (IV-MO) and oral transmucosal fentanyl citrate (OTFC) given in doses proportional to the basal opioid regimen was performed in 25 cancer patients receiving stable opioid doses. For each episode, when it occurred and 15 and 30 min after the treatment, pain intensity and opioid-related symptoms were recorded. Fifty-three couples of breakthrough events, each treated with IV-MO and OTFC, were recorded. In episodes treated with IV-MO, pain intensity decreased from a mean of 6.9 to 3.3 and to 1.7 at T1 and T2, respectively. In episodes treated with OTFC, pain int…

AdultMalecancer painCancer Researchintravenous morphineAdolescentTransmucosal fentanyl; intravenous morphine; episodic-breakthrough pain.Transmucosal fentanylAdministration OralPainFentanylNeoplasmsClinical StudiesmedicineHumansDosingChildOTFCAdverse effectCross-Over StudiesMorphinebusiness.industryInfantopioidsMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenepisodic-breakthrough pain.OncologyOpioidChild PreschoolAnesthesiaInjections IntravenousMorphineFemalebusinessCancer painmedicine.drugBritish Journal of Cancer
researchProduct

A Prospective Randomized Study of Corticosteroids as Adjuvant Drugs to Opioids in Advanced Cancer Patients

2007

This randomized controlled study evaluated the role of corticosteroids as adjuvants to opioid therapy in 76 advanced cancer patients with pain who requiring strong opioids. Patients were divided in 2 groups. Group O received conventional opioid treatment. Group OS received dexamethasone (8 mg orally) along with conventional treatment. Pain and symptom intensity, sense of well-being, and opioid escalation index and distress score were recorded at weekly intervals until death. No differences in pain intensity, opioid consumption, and opioid escalation index were found in 66 patients who survived 33 to 37 days. Corticosteroids did not provide significant additional analgesia to opioids, but p…

AdultMalecorticosteroidmedicine.medical_treatmentAnti-Inflammatory Agentslaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled trial030502 gerontologylawNeoplasmsmedicineHumansProspective Studiesopioids in advanced cancer patientsprospective randomized studyProspective cohort studyDexamethasoneAgedPain MeasurementAged 80 and overAnalysis of VarianceChemotherapyadjuvant drugDose-Response Relationship Drugbusiness.industryPalliative CareGeneral MedicineMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidChemotherapy Adjuvant030220 oncology & carcinogenesisAnesthesiaDrug Therapy CombinationFemale0305 other medical scienceCancer painbusinessAdjuvantFollow-Up Studiesmedicine.drugAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey.

2008

The aim of this national cross-sectional survey was to draw information on pain prevalence and intensity from a large sample of patients who were admitted to oncologic centres for different reasons and to evaluate the pain treatment and possible influencing factors.A total of 2,655 patients completed the study. Nine hundred and one patients (34%) reported pain.Higher pain levels were observed in inpatients, in the presence of bone metastases, and with low levels of Eastern Cooperative Oncology Group status. The number of patients receiving strong opioids increased with the highest levels of pain. However, a significant part of patients with moderate-severe pain were not receiving appropriat…

AdultMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaCross-sectional studyPain medicineMEDLINEPainSeverity of Illness IndexNeoplasmsOncology Service HospitalEpidemiologySeverity of illnessmedicinePrevalenceHumansAgedAged 80 and overPrimary Health Carebusiness.industryCancer painEpidemiologyOpioidsNursing researchPhysicians FamilyMiddle AgedLarge sampleAnalgesics OpioidCross-Sectional StudiesOncologyItalyFamily medicineHealth Care SurveysPhysical therapyFemaleCancer painbusinessSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain

2021

Simple Summary The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain. This prospective study showed that in this population, BTcP prevalence was 69.8%. Many patients did not achieve a sufficient level of satisfaction with BTcP medications, particularly with oral morphine. Data also suggest that better optimization of background analgesia, though apparently acceptable, may limit the number of BTcP episodes. Abstract The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background p…

Cancer Researchmedicine.medical_specialtyPain relieflcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAnalgesic therapyInternal medicineEpidemiologymedicineIn patientOral morphinebreakthrough cancer pain; opioids; dosesbusiness.industryLow doseBreakthrough cancer painlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdosesOpioidsOncologyDose030220 oncology & carcinogenesisCancer painbusiness030217 neurology & neurosurgery
researchProduct

Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit

2020

Aim: To characterize episodic breathlessness (EB) in patients with advanced cancer, and to determine factors influencing its clinical appearance. Methods: A consecutive sample of advanced cancer patients admitted to an acute palliative care unit was surveyed. Continuous dyspnea and EB were measured by a numerical scale. The use of drugs used for continuous dyspnea and EB was recorded. Patients were asked about the characteristics of EB (frequency, intensity, duration and triggers). The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were also administered. Results: From 439 advanced …

Cancer Researchmedicine.medical_specialtyPalliative careEpisodic breathlessneOpioidHospital Anxiety and Depression Scalelcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineInternal medicineMedicineadvanced cancerIn patient030212 general & internal medicinepalliative carebusiness.industryopioidsClinical appearancedyspneaPalliative care.lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAdvanced cancerConfidence intervalrespiratory tract diseasesepisodic breathlessnessOncology030220 oncology & carcinogenesisbusinessCancers
researchProduct

The Association between a MAOB Variable Number Tandem Repeat Polymorphism and Cocaine and Opiate Addictions in Polyconsumers

2021

Genetic analysis of the association between alcohol, cocaine, and opiate addiction and variable number tandem repeat (VNTR) polymorphisms in monoamine oxidase B (MAOB) and serotonergic 5-hydroxytryptamine (serotonin) receptor 1B and 2C (HTR1B 21 and HTR2C) pathway genes was performed in a sample of 302 polyconsumers. Our genetic association analysis revealed a significant association between a 184 base pair (bp) VNTR polymorphism in the MAOB gene and addiction to cocaine and opiates. This work highlights new genetic marker associations in cocaine and opiate polyconsumer addictions. These data help to clarify and quantify the complex role of genetics in addictive disorders, as well as their …

Geneticsbusiness.industryGeneral NeuroscienceAddictionmedia_common.quotation_subjectGenetic counselingMAOBcocaineopioidsNeurosciences. Biological psychiatry. NeuropsychiatrySerotonergicArticlepolymorphismVariable number tandem repeatGenetic markerPharmacogenomicsmental disordersMedicinegeneticsMonoamine oxidase BOpiatepolydrug usebusinessRC321-571media_common
researchProduct